PharmaEssentia surpasses enrollment goals in clinical trials for hematology candidate BESREMi
PharmaEssentia USA Corporation, a key player in biopharmaceutical innovation and a subsidiary of Taiwan-based PharmaEssentia Corporation, has announced a significant milestone in the development of ... Read More
Medidata unveils Clinical Data Studio to transform clinical trials
Medidata, a Dassault Systèmes brand and a key player in clinical trial solutions for the life sciences industry, today announced the launch of Medidata Clinical ... Read More
Enveda Biosciences secures $55m to advance AI-driven drug discovery
Enveda Biosciences, a leader in utilizing artificial intelligence (AI) to convert nature’s chemistry into groundbreaking medicines, has successfully raised an additional $55 million. This funding ... Read More
RemeGen’s RC88 shows promising results in Phase I/II study for advanced solid tumors
RemeGen Co., Ltd., a leader in biopharmaceutical innovation based in China, has unveiled promising results from its Phase I/II clinical study of RC88, a first-in-class ... Read More
FibroGen and Regeneron Pharmaceuticals forge clinical trial collaboration for cancer treatment
FibroGen, Inc. (NASDAQ: FGEN) has entered into a clinical trial supply agreement with Regeneron Pharmaceuticals, aiming to evaluate FibroGen’s immuno-oncology assets, FG-3165 and FG-3175, in ... Read More
Jazz Pharmaceuticals’ zanidatamab shows promising results in HER2-positive biliary tract cancer
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) has released pivotal new data from its Phase 2b HERIZON-BTC-01 clinical trial assessing zanidatamab in previously treated HER2-positive biliary tract ... Read More
Gilead and Arcus announce significant advancement in metastatic colorectal cancer treatment with etrumadenant plus zimberelimab regimen
Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences, Inc. (NYSE: RCUS) have released promising new data from their collaborative study, ARC-9, during an oral session ... Read More
Dizal’s sunvozertinib shows promising results in global pivotal lung cancer study
Dizal, a prominent biopharmaceutical company listed on the Shanghai Stock Exchange (SSE:688192), has announced significant clinical results from its WU-KONG1 Part B (WU-KONG1B) study of ... Read More
Voydeya approved in EU for enhanced treatment of PNH with residual haemolytic anaemia
Voydeya (danicopan), a first-in-class oral Factor D inhibitor from Alexion, AstraZeneca Rare Disease, has received approval from the European Commission as an add-on treatment to ... Read More
Lilly announces significant results in SURMOUNT-OSA trials of tirzepatide in OSA
Eli Lilly and Company (NYSE: LLY) has released positive topline results from the phase 3 SURMOUNT-OSA clinical trials, demonstrating that tirzepatide injection significantly reduces the ... Read More